Project Grant R43DA066396
Award Date 8/15/26
Completion Date 7/31/27
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Menlo Park, CA 94025, USA
Similar Awards
- The National Institute on Drug Abuse awarded Praeventix LLC $355,190 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct in vivo characterization of 5-HT7 modulators in rat models of opioid use disorder. The work evaluates the impact of the lead compound PRA078, a novel 5-HT7 antagonist, on dopamine pathways and cognitive flexibility in animal models of opioid dependence. The research addresses therapeutic gaps in opioid use disorder treatment, where...
- The National Institute on Drug Abuse awarded Yale University $659,834 on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate cannabinoid receptor type 1 (CB1R) availability in individuals with opioid use disorder. The study uses [11C]OMAR PET imaging to assess CB1R availability in 55 early abstinent individuals with opioid use disorder following inpatient buprenorphine stabilization and 55 matched healthy controls (total N=110). Individuals with...
- The National Institute on Drug Abuse awarded the University of Southern California $108,000 on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the molecular mechanisms of a kappa opioid receptor selective negative allosteric modulator as a potential therapeutic approach to opioid addiction and overdose. The research seeks to elucidate the structural and functional basis of kappa opioid receptor modulation through negative allosteric...
- The National Institute on Drug Abuse awarded The McLean Hospital Corporation $736,811 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a longitudinal cohort study of opioid use disorder. The project characterizes the long-term course of opioid use disorder through remote follow-up of 550 adults with opioid use disorder recruited from sites across the United States. The study employs monthly patient-reported outcomes and annual...
- The National Institute on Drug Abuse awarded Transchromix LLC $399,994 on July 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a therapeutic strategy targeting non-fatal opioid overdose-induced hypoxia-related brain injuries. The recipient will develop MS1262, a novel G9A inhibitor previously characterized as effective in Alzheimer's disease models, as a treatment for complications arising from respiratory suppression and hypoxia following non-fatal opioid...
- The National Institute on Drug Abuse (NIDA), within the Department of Health and Human Services, awarded Massachusetts General Hospital $451,670 on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support final preclinical evaluation of a positron emission tomography neuroimaging probe for measuring mu opioid receptor density and occupancy in the human brain. The award funds development and validation of 18F-fluorocarfentanil (18F-FCFN) derivatives as safe,...
- The National Institute on Drug Abuse awarded The Johns Hopkins University $466,363 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to characterize allosteric crosstalk among opioid and endogenous neuromodulator receptors. The project uses cryo-electron microscopy to determine high-resolution structures of the mu-opioid receptor in active and inactive states bound to cannabinoids and neuropeptides including oxytocin. The work advances time-resolved cryo-EM...
- The National Institute on Drug Abuse awarded Virginia Commonwealth University a $3.444 million cooperative agreement on September 15, 2025, to develop preliminary safety and early efficacy data for VVZ-2471, a novel 5-HT2A and mGluR5 antagonist candidate for opioid use disorder under the Drug Use and Addiction Research Programs (CFDA 93.279). VVZ-2471, developed by Vivozon Inc in collaboration with VCU, demonstrated in preclinical studies the ability to reduce morphine self-administration and...
- The National Institute on Drug Abuse awarded Cessation Therapeutics, Inc. a Cooperative Agreement of $7.315 million on September 15, 2025, to advance clinical development of CSX-1004, a human IgG1 monoclonal antibody designed to provide prophylaxis against fentanyl and fentanyl analog overdose. The award funds Phase 2 proof-of-concept fentanyl challenge studies in healthy subjects and subjects with opioid use disorder, with the ultimate target product profile being a fixed-dose subcutaneous...
- The National Institute on Drug Abuse awarded Brown University $480,276 under the Drug Use and Addiction Research Programs (CFDA 93.279) on July 1, 2026, to co-develop a brief intervention with young adults aged 18–25 who have opioid use disorder and prematurely terminated treatment, aimed at reducing overdose risk and reengaging participants in evidence-based medication for opioid use disorder (MOUD). The K99/R00 award funds two phases of research. During the K99 phase, the project will...